Search
Zimlovisertib
go.drugbank.com/drugs/DB15143InvestigationalPF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Epafipase
go.drugbank.com/drugs/DB16158InvestigationalEpafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis).
Aminocandin
go.drugbank.com/drugs/DB05128ExperimentalAminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Piritrexim
go.drugbank.com/drugs/DB03695InvestigationalPiritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional Cell Cancer of the Renal Pelvis and Ureter.
Hypoxanthine
go.drugbank.com/drugs/DB04076InvestigationalHypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Sedecamycin
go.drugbank.com/drugs/DB21342ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Sedecamycin is a antibiotic, produced by Streptomyces strain. Sedecamycin has a monoisotopic molecular weight of 501.24 Da.
Ambasilide
go.drugbank.com/drugs/DB19463ExperimentalThe usage of the INN stem '-ilide' in the name indicates that Ambasilide is a sematilide derivative class III antiarrhythmic. Ambasilide has a monoisotopic molecular weight of 335.2 Da.
Bitipazone
go.drugbank.com/drugs/DB19941ExperimentalThe usage of the INN stem '-azone' in the name indicates that Bitipazone is a anti-inflammatory analgesic, phenylbutazone derivative. Bitipazone has a monoisotopic molecular weight of 454.27 Da.
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.